MX2011007600A - Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos. - Google Patents

Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos.

Info

Publication number
MX2011007600A
MX2011007600A MX2011007600A MX2011007600A MX2011007600A MX 2011007600 A MX2011007600 A MX 2011007600A MX 2011007600 A MX2011007600 A MX 2011007600A MX 2011007600 A MX2011007600 A MX 2011007600A MX 2011007600 A MX2011007600 A MX 2011007600A
Authority
MX
Mexico
Prior art keywords
oxadiazole
carboline derivatives
antidiabetic compounds
beta
beta carboline
Prior art date
Application number
MX2011007600A
Other languages
English (en)
Inventor
William K Hagmann
Shuwen He
Wu Du
Zhong Lai
Shrenik K Shah
Quang T Truong
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2011007600A publication Critical patent/MX2011007600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los derivados de beta-carbolina de fórmula estructural I son antagonistas selectivos del receptor de somatostatina subtipo 3 (SSTR3) y son útiles para el tratamiento de diabetes mellitus de Tipo 2 y de afecciones que están asociadas frecuentemente con esta enfermedad, incluyendo hiperglucemia, resistencia a la insulina, obesidad, trastornos lipídicos e hipertensión; los compuestos también son útiles para el tratamiento de depresión y la ansiedad. (ver fórmula (I)).
MX2011007600A 2009-01-16 2010-01-12 Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos. MX2011007600A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20545109P 2009-01-16 2009-01-16
PCT/US2010/020695 WO2010083136A1 (en) 2009-01-16 2010-01-12 Oxadiazole beta carboline derivatives as antidiabetic compounds

Publications (1)

Publication Number Publication Date
MX2011007600A true MX2011007600A (es) 2011-08-17

Family

ID=42229250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007600A MX2011007600A (es) 2009-01-16 2010-01-12 Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos.

Country Status (10)

Country Link
US (1) US20100184799A1 (es)
EP (1) EP2387574A1 (es)
JP (1) JP2012515204A (es)
CN (1) CN102282146A (es)
AR (1) AR074994A1 (es)
AU (1) AU2010204912A1 (es)
CA (1) CA2748831A1 (es)
MX (1) MX2011007600A (es)
TW (1) TW201028414A (es)
WO (1) WO2010083136A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785790A1 (en) * 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
SI3004090T1 (en) 2013-05-28 2018-01-31 Astrazeneca Ab Chemical compounds
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
MX2022005139A (es) * 2019-11-04 2022-06-24 Recurium Ip Holdings Llc Sales y formas de un modulador de receptores estrogénicos.
TW202200554A (zh) 2020-03-16 2022-01-01 瑞士商諾華公司 作為ｙａｐ／ｔａｚ—ｔｅａｄ蛋白—蛋白相互作用抑制劑之聯芳基衍生物
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU761020B2 (en) * 1998-06-12 2003-05-29 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Beta-carboline compounds
US6890933B1 (en) * 2000-02-24 2005-05-10 President And Fellows Of Harvard College Kinesin inhibitors
AU2001277056B2 (en) 2000-07-25 2005-09-29 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
AU2003265681A1 (en) 2002-08-29 2004-03-19 Merck And Co., Inc. Indoles having anti-diabetic activity
CA2562082C (en) 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
US7879859B2 (en) * 2005-11-21 2011-02-01 Merck Sharp & Dohme Corp. Diagnosis and treatment of type 2 diabetes and other disorders
JP2010533712A (ja) * 2007-07-19 2010-10-28 メルク・シャープ・エンド・ドーム・コーポレイション 抗糖尿病化合物としてのベータカルボリン誘導体

Also Published As

Publication number Publication date
WO2010083136A1 (en) 2010-07-22
CA2748831A1 (en) 2010-07-22
JP2012515204A (ja) 2012-07-05
AR074994A1 (es) 2011-03-02
TW201028414A (en) 2010-08-01
US20100184799A1 (en) 2010-07-22
CN102282146A (zh) 2011-12-14
AU2010204912A1 (en) 2011-07-28
EP2387574A1 (en) 2011-11-23

Similar Documents

Publication Publication Date Title
MX2011007600A (es) Derivados de oxadiazol beta carbonica como compuestos anti-diabeticos.
EP2571356A4 (en) SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS
WO2008054675A3 (en) Antidiabetic bicyclic compounds
EA015805B9 (ru) Пиперидиновые агонисты gpcr
PE20091324A1 (es) Compuestos espiro como antagonistas del receptor npy y5
HK1135703A1 (en) Piperidine gpcr agonists
NZ764889A (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
EA201170305A1 (ru) Аналоги глюкозозависимого инсулинотропного полипептида (gip), модифицированные по n-концу
CL2008003847A1 (es) Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
HK1158192A1 (en) Piperidine gpcr agonists
WO2010016940A3 (en) Analogues of glucose-dependent insulinotropic polypeptide
WO2007116230A8 (en) Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists
WO2008054674A3 (en) Antidiabetic bicyclic compounds
ECSP10010231A (es) Derivados de 7-azaindol como inhibidores selectivos de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1.
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
CL2008000198A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2007003261A1 (es) Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, tales como esquizofrenia,
PE20090741A1 (es) Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano
EA201170302A1 (ru) Процессированные аналоги глюкозозависимого инсулинотропного полипетида
CL2007003440A1 (es) Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2010016938A3 (en) Glucose-dependent insulinotropic polypeptide analogues
WO2012054526A3 (en) Chemosensory receptor ligand-based therapies
HK1145498A1 (en) Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
GB0812642D0 (en) Compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal